New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2012
16:19 EDTAAMRQ, JNJ, REGN, LCC, JPM, CASY, RMBSOn The Fly: Closing Wrap
Stocks on Wall Street were lower following disappointing U.S. economic data. Stock futures were lower in premarket trading but tumbled following disappointing retail sales figures for the month of May. The market opened lower but soon found a level from where it started to build. The averages crossed into positive territory could not gain any upside momentum. The middle of the day was characterized by the market drifting back and forth across the baseline as it underwent a period of consolidation, in contrast to the previous two days, which were marked by big swings in the averages. In the last hour of trading the market fell sharply to wind up down for the day… ECONOMIC EVENTS: In the U.S., retail sales slipped 0.2%, which was in line with expectations, but if auto and gasoline data are excluded the "core" reading showed a decline of 0.1%, versus expectations of an increase of 0.4%. Producer prices in the month of May declined 1.0%, versus expectations of a decline of 0.6%, but if food and energy are removed the reading was up 0.2%, which was in line with forecasts. Business inventories grew 0.4% in April, versus expectations for an increase of 0.3%. In Europe, Italy’s national borrowing rate skyrocketed to its highest level since December, as investors became jittery about contagion from Spain’s request for external assistance… COMPANY NEWS: JPMorgan's (JPM) CEO Jamie Dimon testified in front of the Senate Banking Committee, saying that he expects the current quarter to be "solidly profitable" in spite of the "London Whale's" losses and that clawbacks of executive pay are likely following the bank's review of the incident. Dimon argued that complex institutions are necessary to meet the needs of business and that there are many advantages and only some negatives to big banks. Following his testimony JPMorgan’s shares rose 53c, or 1.57%, to $34.30... Johnson & Johnson (JNJ) shares rose $1.37, or 2.17%, to $64.45, after JPMorgan, Jefferies and Raymond James all upgraded the stock this morning. Last night, the pharmaceutical giant confirmed it has received U.S. regulatory clearance for its proposed acquisition of Synthes and announced a new accelerated share repurchase agreement... MAJOR MOVERS: Among the notable gainers were Rambus (RMBS), up 44c, or 9.16%, to $5.30, after being initiated with a Buy rating and $10 price target at Sidoti, and U.S. Airways (LCC), up 54c, or 4.72%, to $11.97, after multiple sources indicated that the company plans to file paperwork with U.S. antitrust regulators as soon as next month for a proposed merger with AMR (AAMRQ). Noteworthy losers included Casey’s General Stores (CASY), down $7.73, or 12.90%, to $52.18, after missing on Q4 EPS, and Regeneron (REGN), down $15.97, or 12.49%, to $111.88, after competitor Ophthotech announced positive data from a clinical trial… INDICES: The Dow lost 77.42, or 0.62%, to 12,496.38; the Nasdaq fell 24.46, or 0.86%, to 2,818.61; and the S&P 500 dropped 9.30, or 0.70%, to 1,314.88.
News For JPM;JNJ;RMBS;LCC;AAMRQ;CASY;REGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 13, 2015
15:18 EDTJPMJPMorgan technical notes ahead of earnings
The shares are trading close to the 52-week high which is at $63.49. On strongly positive news, the stock would be pushed toward the life high at $67.17. That would be an important technical milestone if it was reached. Traders should note however that that move would on a long-term basis appear as a move up to prior resistance without being a bullish breakout. Until or if there is a breakout above the old life high, there is retracement risk even on good results. On news that is more bearish than current expectations would suggest, first major support would be at the 50-day moving average at $60.10. On a move below that level, next support would be at $57.87.
15:10 EDTJPMJPMorgan April 62 straddle priced for 2.6% movement into Q1
Subscribe for More Information
15:08 EDTJNJJohnson & Johnson April 100 straddle priced for 2.2% movement into Q1
14:07 EDTJNJEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
13:57 EDTJPMEarnings Watch: Analysts upbeat on JPMorgan ahead of Q1 results
Subscribe for More Information
13:28 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Subscribe for More Information
11:12 EDTJNJJohnson & Johnson technical notes before earnings
Leading up to earnings, the shares have been trading in a narrow range largely bound by $98 at the low and $103 at the high. This trading range was preceded by a decline from the 52-week high set back in the fall of 2014. In a longer time frame, the current trading action is part of a larger potential topping process, with $95 as the midpoint. On worse than expected news, the low bound at $98 would be first important support. A breakdown below $98 would see next support at $95. A move below $95 would confirm the topping process and break the long-term uptrend. Support below $95 would be at $93.94. If results and outlook are better than expected, first resistance would be at the top of the range at $103. Next resistance would then be at $105.36. A move above that level would see $107.10, and then 52-week high and life high at $109.49 as next potential upside objectives.
11:12 EDTJPMJP Morgan April volatility elevated into Q1 and outlook
Subscribe for More Information
April 10, 2015
14:39 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Johnson & Johnson April call option implied volatility is at 20, May is at 16, June is at 15, October is at 14; compared to its 26-week average of 16 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 14.
14:18 EDTJPMJP Morgan April volatility elevated into Q1 and outlook
Subscribe for More Information
07:17 EDTREGNExpert very bullish on outlook for Regeneron Eylea, says RBC Capital
RBC Capital reports that a retina expert with whom it spoke was "very bullish" on the outlook for Regeneron's Eylea, not just in DME but also in wet AMD. The firm says the expert's positive outlook was sparked by recently presented Protocol T data. RBC continues to believe that Eylea could beat guidance this year, while Phase III programs could boost the stock. RBC keeps a $490 price target and Outperform rating on the shares.
06:21 EDTJPMBofA Merrill poaches JP Morgan's Brabazon for M&A group, Reuters reports
Subscribe for More Information
April 9, 2015
09:25 EDTJNJPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
07:13 EDTJPMJPMorgan CEO sees legal cost normalizing next year, WSJ reports
Subscribe for More Information
06:55 EDTJPMJPMorgan added to U.S. Focus List at Credit Suisse
Credit Suisse added Outperform rated JPMorgan to the U.S. Focus List to reflect balance sheet optimization and balance sheet deployment, and catalysts that include clarification mandated domestic GSIB capital surcharges and continued fundamental performance.
April 8, 2015
09:23 EDTJNJJohnson & Johnson April volatility elevated into Q1 and outlook
Subscribe for More Information
07:24 EDTJNJNeurotechnology Industry Organization to hold a conference
Subscribe for More Information
April 7, 2015
10:05 EDTJPMOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Carnival (CCL) upgraded to Outperform from Market Perform at Wells Fargo... Crown Castle (CCI) upgraded to Buy from Hold at Evercore ISI... Ctrip.com (CTRP) upgraded to Overweight from Neutral at Piper Jaffray... Demandware (DWRE) upgraded to Conviction Buy from Buy at Goldman... FirstEnergy (FE) upgraded at BofA/Merrill... Frontier Communications (FTR) upgraded to Neutral from Underperform at DA Davidson... JPMorgan (JPM) upgraded to Outperform from Market Perform at Bernstein... Pattern Energy (PEGI) upgraded to Outperform from Market Perform at Raymond James... Ralph Lauren (RL) upgraded to Buy from Outperform at CLSA... ResMed (RMD) upgraded to Outperform from Neutral at Credit Suisse... Ryanair (RYAAY) upgraded to Overweight from Neutral at JPMorgan... Splunk (SPLK) upgraded to Overweight from Neutral at Piper Jaffray... Total (TOT) upgraded at RBC Capital... Verifone (PAY) upgraded to Buy from Hold at Stifel... XL Group (XL) upgraded to Buy from Neutral at UBS.
09:08 EDTJPMGoldman says buy JPMorgan, Signature Bank, and Regions Financial into Q1
Subscribe for More Information
07:18 EDTJPMJPMorgan upgraded to Outperform from Market Perform at Bernstein
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use